Industry recommendations: Layout of pharmaceutical manufacturing upgrades in 2022, focusing on the upstream of biomedicine

The A-share pharmaceutical sector in 2021 is considered by the industry to be a year of shock digestion of valuations after many years of bull market
.
Looking back on this year, the internal structure of the pharmaceutical sector has clearly differentiated.
Among them, the performance of the CXO segment is still very prominent.
The medical service sector has recorded an increase of more than 21%, and the Chinese medicine sector has also increased by 25%
.
Now that it is the end of the year, looking forward to 2022, is there still a chance for the pharmaceutical sector? How should it be laid out? There are suggestions from the industry that it is possible to lay out the upgrade field of pharmaceutical manufacturing and pay attention to the upstream of biomedicine
.
What are the investment strategies for the pharmaceutical sector in 2022? Regarding the investment strategy of the pharmaceutical sector in 2022, many securities firms have recently released research reports or investment strategies.
On the whole, the structural opportunities of the pharmaceutical sector next year are still promising, and the giants in the sub-sector are more concerned
.
For example, Industrial Securities suggested in its research report that the main line of investment in medicine should focus more on the company's "non-new crown" main business, layout industry giants, and tap potential rookies
.
Soochow Securities believes that this year's medical structure has become more differentiated.
Innovative drugs, medical devices, biological products, etc.
may become the main growth drivers of the industry, and the pharmaceutical sector will still be a sector with high growth certainty in 2022
.
Recently, Guosheng Securities analysts also released a research report.
From the main point of view, they recommend the deployment of manufacturing upgrades, technological upgrades, and consumption upgrades in 2022
.
Among them, in the field of pharmaceutical manufacturing upgrades, Guosheng Securities believes that from the perspective of emerging 4+X segment trends, pharmaceutical manufacturing upgrades are strong, with little policy disturbances and long-term logical support areas that are more favored by investors, such as the upstream of biomedicine.
and international preparations, innovation and industrial chain CRO CDMO & CMO sector, it is recommended to focus on stocks, including Gloria Britain, Bo Teng shares, Jiuzhou Pharmaceutical, Stellite, Tung Fu Long, Chutian science and technology
.
Upstream of biomedicine attracts attention In the first three quarters of 2021, the performance of the pharmaceutical manufacturing industry is stable
.
Data show that as of September 2021, the pharmaceutical manufacturing industry has achieved a total revenue of 2,219.
1 billion yuan, a year-on-year increase of 24.
4%; a total profit of 4,525.
3 billion yuan, a year-on-year increase of 80.
6%
.
From the perspective of the development of the pharmaceutical market, in recent years, with the rapid development of biotechnology, the domestic biopharmaceutical market has ushered in a trend.
A group of biopharmaceutical companies represented by popular drugs such as antibody drugs, such as Hengrui Pharmaceuticals, Qilu Pharmaceuticals, and Zhengda Tianqing and others have gradually emerged, occupying an increasingly important position in the medical field, and have huge growth potential
.
Data shows that with the increase in residents' affordability and the expansion of medical insurance coverage, it is estimated that the size of China's biopharmaceutical market in 2021 will exceed 317.
2 billion yuan in 2019, breaking through the 400 billion yuan mark to 464.
4 billion yuan
.
In the context of the rapid development of biomedicine, upstream product development and raw material production have also attracted much attention
.
From the report of the first three quarters of 2021, the leading domestic biopharmaceutical production equipment companies mainly present the following characteristics: the proportion of biopharmaceutical equipment in the company has increased rapidly; R&D investment has achieved rapid growth, and R&D investment accounts for the proportion of total revenue Rapid improvement; some companies have shown the effect of new products through the early R&D layout; domestic substitution has accelerated and the international layout has become more in-depth
.
With the rapid development of the biopharmaceutical industry, the industry predicts that in 2022, the upstream including biopharmaceutical equipment will also usher in more opportunities
.
What needs to be noticed is that although domestic back-end equipment including filling lines and post-packaging lines can basically meet the needs of biopharmaceutical companies, high-end biopharmaceutical equipment, such as front-end equipment with relatively high technical difficulty, includes reaction The domestic market is still dominated by foreign pharmaceutical giants, such as equipment, separation and purification systems.
Therefore, the development of high-end equipment will be the goal of domestic enterprises in the next phase
.
The industry predicts that in the future, domestic biopharmaceutical equipment companies such as Dongflon and Chutian Technology are expected to accelerate the pace of import substitution and achieve new growth
.
Pharmaceutical equipment (Image source: Pharmaceutical Network)